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Abstract
Purpose Rapid antigen-detecting tests (Ag-RDTs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can 
transform pandemic control. Thus far, sensitivity (≤ 85%) of lateral-flow assays has limited scale-up. Conceivably, micro-
fluidic immunofluorescence Ag-RDTs could increase sensitivity for SARS-CoV-2 detection.
Methods This multi-centre diagnostic accuracy study investigated performance of the microfluidic immunofluorescence 
LumiraDx™ assay, enrolling symptomatic and asymptomatic participants with suspected SARS-CoV-2 infection. Participants 
collected a supervised nasal mid-turbinate (NMT) self-swab for Ag-RDT testing, in addition to a professionally collected 
nasopharyngeal (NP) swab for routine testing with reverse transcriptase polymerase chain reaction (RT-PCR). Results were 
compared to calculate sensitivity and specificity. Sub-analyses investigated the results by viral load, symptom presence 
and duration. An analytical study assessed exclusivity and limit-of-detection (LOD). In addition, we evaluated ease-of-use.
Results The study was conducted between November 2nd 2020 and 4th of December 2020. 761 participants were enrolled, 
with 486 participants reporting symptoms on testing day. 120 out of 146 RT-PCR positive cases were detected positive by 
LumiraDx™, resulting in a sensitivity of 82.2% (95% CI 75.2–87.5%). Specificity was 99.3% (CI 98.3–99.7%). Sensitivity 
was increased in individuals with viral load ≥ 7 log10 SARS-CoV2 RNA copies/ml (93.8%; CI 86.2–97.3%). Testing against 
common respiratory commensals and pathogens showed no cross-reactivity and LOD was estimated to be 2–56 PFU/mL. 
The ease-of-use-assessment was favourable for lower throughput settings.
Conclusion The LumiraDx™ assay showed excellent analytical sensitivity, exclusivity and clinical specificity with good 
clinical sensitivity using supervised NMT self-sampling.
Trial registration number and registration date DRKS00021220 and 01.04.2020
Keywords SARS-CoV-2 · Covid-19 · Diagnostic accuracy · Antigen-detecting diagnostics · Point-of-care
Introduction
The SARS-CoV-2 pandemic has caused over 100 million 
confirmed infections worldwide, stated by the World Health 
Organization (WHO) [1]. Reverse transcriptase polymerase 
chain reaction (RT-PCR) has been established as the gold 
standard for diagnosing individuals infected with SARS-
CoV-2 [2]. Because RT-PCR testing requires advanced labo-
ratory infrastructure demanding numerous predefined mate-
rials and specially trained staff, testing capacities in many 
countries have at times been pushed to their limits. Also, the 
longer turn-around time for results from laboratory-based 
RT-PCR testing does not allow for rapid decision-making, 
often taking days until results are available, thus identifying 
infected individuals is often too late to prevent secondary 
cases [3].
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SARS-CoV-2 rapid antigen-detecting tests (Ag-RDTs) can 
be considered complementary to RT-PCR for rapid testing, 
or as an alternative for RT-PCR in settings where resources 
and laboratory infrastructure are limited as suggested by the 
WHO [4]. Several countries are incorporating these tests 
into their national testing strategies and some (e.g., Slovakia 
and the United Kingdom) are utilizing them for large-scale 
screening [5].
Most tests on the market use the lateral flow principle [6]. 
While many tests have shown excellent specificity, sensitiv-
ity in several independent evaluations has been around 85% 
or less [7–10]. Conceivably, microfluidic immunofluores-
cence combined with digital result capture and connectivity 
could boost sensitivity and ease of use of Ag-RDTs [11].
LumiraDx™ has recently developed a diagnostic device 
using microfluidic immunofluorescence technology with 
automated read-out to enable rapid detection of SARS-CoV-2 
antigen from a nasal mid-turbinate (NMT) swab [12]. In 
the United States, the LumiraDx™ SARS-CoV-2 Ag-RDT 
was granted an emergency use authorization by the Federal 
Drug Agency (FDA) in August 2020 [13]. In the United 
Kingdom, a large pharmacy chain offers LumiraDx™ SARS-
CoV-2 testing at the point-of-care [14]. To date, there is only 
one publication available, sponsored by the manufacturer 
that reported a 97.6% sensitivity and 96.6% specificity [15] 
in nasal swabs from mostly symptomatic persons within 
12 days of symptom onset.
This multi-centre, manufacturer-independent diagnos-
tic accuracy study investigated the performance, ease-of-
use, exclusivity, and limit-of-detection of the microfluidic 




The diagnostic test under evaluation in this study was the 
microfluidic immunofluorescence assay, SARS-CoV-2 Ag 
test developed by LumiraDx™ Limited, London, United 
Kingdom (henceforth called LumiraDx™). The assay runs 
on a portable platform using a dry, single-use, disposable, 
microfluidic test strip. The strip contains antibodies specific 
to the nucleocapsid protein of SARS-CoV-2 that form a sand-
wich-like immuno-complex and emit a fluorescent signal if 
the nucleocapsid protein is detected [12].
The sample collection was performed with Dryswab™ 
Standard Tip Rayon (Medical Wire & Equipment, Cor-
sham, England), not included in the test kits, but rec-
ommend for use by the manufacturer. Ag-RDT testing 
was performed on-site in a dedicated workspace that 
was divided into separate areas where infectious and 
non-infectious materials were handled. Laboratory per-
sonal for Ag-RDT testing was blinded to the results of 
RT-PCR testing and vice versa. Following manufacturer 
instructions for use, the collected sample was processed 
using the LumiraDx™ proprietary extraction buffer vial 
for ten seconds. A single-use test strip was placed in 
the designated slot on the testing device, and one drop 
(~ 20 μL) of the prepared extraction buffer solution was 
applied. The designated device slot was closed to initi-
ate automatic processing and testing. The device showed 
a qualitative result (“positive”, “negative” or “error”) on 
the digital touch screen within 12 minutes. In case of an 
erroneous test result, the testing was immediately repeated 
using the solution from the same extraction vial and a new 
test strip.
For every test, a cut-off-index (COI) value was auto-
matically generated and documented in the testing device, 
reporting the test immunofluorescent signal on a continu-
ous scale with a pre-set cut-off categorizing the results 
as positive or negative. COI values were retrieved from 
the test devices by the manufacturer after completion of 
the study. The device can operate in a cloud-based mode 
enabling the manufacturer to receive all impersonal data 
through an online connection. During this study, the manu-
facturer could not access the device as the study was per-
formed offline.
After every test, the surface of the device was disinfected 
with proprietary disinfection wipes provided by the com-
pany. A 5-minute drying time was recommended before the 
next sample was inserted, following the manufacturer infor-
mation for use [12].
Reference test
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
was used as the reference test. The RT-PCR samples were 
collected by health-care workers using the  IMPROSWAB® 
(Guangzhou Improve Medical Instruments Co., Ltd., Guang-
zhou, China) at the Heidelberg study site and the eSwab™ 
(Copan Diagnostics Inc., Murrieta, CA, USA) at the study 
site in Berlin. Collected samples were transferred to the 
referral laboratories for RT-PCR testing in Heidelberg and 
Berlin. The RT-PCR assays, referral laboratory standard 
assays, used for clinical diagnosis as comparators were All-
plex™ SARS-CoV-2 assay (Seegene, Seoul, South Korea) in 
Heidelberg and cobas™ SARS CoV-2 assay on the  cobas® 
6800 or 8800 system (Roche, Pleasanton, CA, United States) 
or the SARS CoV-2 assay from TIB Molbiol (Berlin, Ger-
many) in Berlin. Interpretation of the RT-PCR assays fol-
lowed the manufacturers’ instructions. The RT-PCR assays 
targeted the E gene of SARS-CoV-2, which was used for 
the CT-value determination and the viral load calculations. 
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Based on testing of standardized material, CT-values of 
the three tests are expected to differ by around 2–3 with 
the same amount of virus present [2]. The conversion of 
CT-values into viral-load was based on calibrated RT-PCR 
testing with quantified SARS-CoV-2 in vitro transcripts [2].
Clinical diagnostic accuracy
The standards for reporting diagnostic accuracy studies 
(STARD) were followed for reporting of this study [16].
Study design and inclusion criteria
This prospective multi-centre study enrolled participants 
at two sites, Heidelberg and Berlin, Germany. In Heidel-
berg, participants were enrolled at a drive-in testing site 
whereas in Berlin participants were enrolled at a clinical 
ambulatory testing facility. All participants were identified 
for testing according to the criteria of the national health 
authority as being at risk of SARS-CoV-2 infection based on 
reported symptoms or recent contact with a confirmed case 
[17]. Inclusion criteria were a minimum age of 18 years and 
no prior positive RT-PCR result for SARS-CoV-2. Written 
informed consent was obtained from each participant prior 
to testing. Individuals unable to give written informed con-
sent due to limited command of German or English were 
excluded from the study. The study protocol is available 
upon request.
Sample collection
The sample for the Ag-RDT was a NMT, following the defi-
nition from the Centers for Disease Control and Prevention 
[18]. This swab was collected by the participants themselves, 
with a health-care worker providing instructions, supervision 
and corrections according to the instruction for use by the 
manufacturer. The participants were instructed to tilt their 
head back 70°, insert the swab approximately 2 cm into one 
nostril, and to rotate it several times against the full interior 
nasal wall surface for at least 10 s. The identical procedure 
was repeated with the same swab in the contralateral nostril.
Subsequently, the professional-collected routine swab for 
RT-PCR testing was taken, following institutional proce-
dures with a nasopharyngeal (NP) swab (Heidelberg) or a 
combined NP/oropharyngeal (OP) swab (Berlin). Partici-
pants underwent OP swabbing only if there were clinical 
contraindications for NP sampling.
Questionnaire
All participants were asked for information on comorbidi-
ties, symptom presence and duration, and severity of disease 
(questionnaire available in the supplement material, Section 
(B)). For data collection, we used the Research Electronic 
Data Capture (REDCap) tools hosted at Heidelberg Univer-
sity [19].
RT‑PCR from Ag‑RDT extraction buffer
All false-positive and false-negative Ag-RDT results were 
retested with RT-PCR from the Ag-RDT proprietary buffer 
solution that was stored at a temperature of − 20 °C, if 
sufficient volume was available. This testing is not vali-
dated by the manufacturer but was performed to resolve 
discrepant results that could have occurred due to vari-
ability between the NP and NMT sampling for RT-PCR 
and Ag-RDT. To avoid the introduction of a discrepant 
analysis bias, a subset of samples (first 5 per day in the 
first 2 weeks) was also re-tested with RT-PCR from the 
antigen buffer.
Exclusivity testing
Clinical samples from common respiratory tract pathogens 
or commensals were assessed for cross-reactivity. The res-
piratory swab samples contained four seasonal coronavi-
ruses, adenovirus, bocavirus, influenza virus, metapneu-
movirus, parainfluenza virus, respiratory syncytial virus, 
rhinovirus or Mycoplasma pneumoniae as identified by 
RT-PCR in the laboratory. For Staphylococcus aureus and 
Streptococcus sp. swab samples from bacterial culture were 
utilized. As recommended by the manufacturer these sam-
ples were added to the extraction buffer in a 1:10 dilution 
(30 µL sample and 270 µL extraction buffer) and processed 
according to the standard test protocol.
Limit‑of‑detection assay using cell culture‑grown 
SARS‑CoV‑2
The limit-of detection of the LumiraDx™ was assessed in 
comparison with Abbott PanBio (Chicago, Illinois, USA) 
and SD Biosensor Standard Q (Gyeonggi-do, Korea), Two 
strains of SARS-CoV-2 were used. The BavPat1/2020 strain 
was kindly provided by Christian Drosten through the Euro-
pean Virus Archive and the HD strain was isolated from a 
patient at the Heidelberg clinic. Working virus stocks were 
generated by passaging the virus two times in VeroE6 cells 
or Calu3 cells (a kind gift from Dr. Manfred Frey, Man-
nheim). Virus stocks were tittered using a plaque forming 
 L. J. Krüger et al.
1 3
unit (PFU) assay [20]. The stock was pre-diluted in DMEM 
supplemented with 2% FCS to 10,000 PFU/mL. Then two-
fold dilutions were generated and added 1:1 to the isola-
tion buffer provided for each test kit. Following this, the 
manufacturer’s protocol for each kit was used. Note, that the 
amount of volume used for each kit was slightly different 
according to the protocols (50 µL for Abbott PanBio, 100 µL 
for Biosensor Standard Q and 35 µL for LumiraDx™). The 
limit of detection was calculated based on the number of 
PFUs in this volume. Three replicates were done for each 
dilution.
System usability scale and ease‑of‑use assessment
To determine and quantify the usability of the test, a stand-
ardized System Usability Scale (SUS) questionnaire was 
used and a dedicated ease-of-use assessment (EoU) was 
developed. The detailed surveys are provided in the sup-
plement material (Section (C) and (D)). Staff performing 
the testing at both study sites were invited to complete the 
questionnaires. A SUS score above 68 is interpreted as above 
average [21]. For the visualization of the EoU assessment a 
colour-coded rating (heat-map) was generated. Each aspect 
of the assessment was ranked as satisfactory, average, or 
unsatisfactory. The supplement material (Section (E)) shows 
the matrix used for this analysis.
Statistics
To determine sensitivity and specificity of the Ag-RDT (with 
95% CIs), results were compared to RT-PCR results from 
the same participant, as per Altman [22]. Predefined sub-
analyses were conducted for presence of symptoms, duration 
of symptoms (≤ 7 days, > 7 days and > 12 days), CT-values 
(using two categorizations: ≤ 25, > 25 and ≤ 30, > 30), viral 
load  (log10 SARS-CoV2 RNA copies/ml), and study site. A 
two-sided alpha value of 0.05 was defined as a significance 
cut-off. We used “R” version 4.0.3. (R Foundation for Sta-
tistical Computing, Vienna, Austria) to generate all analyses 
and plots.
Results
A total of 826 participants were screened for enrolment 
between the 2nd November and 4th December 2020 across 
two study sites, and 767 (92.9%) participants gave written 
informed consent. Of the 767 participants, 493 were enrolled 
in Heidelberg and 274 in Berlin. Two participants were 
Fig. 1  Study flow
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excluded after enrolment as the NMT swab was refused and 
four participants were excluded during analysis due to inva-
lid RT-PCR results, resulting in 761 participants included in 
the analysis (Fig. 1).
Table 1 shows the clinical and demographic character-
istics of all enrolled participants. The median age of the 
participants was 35.0  years (IQR 27.0–49.0) with 52% 
female and 31.7% with comorbidities (Table 1). Symptoms 
on the testing day were reported by 64% of participants, 
with an average symptom duration of 3.9 days (SD 3.2). 
In the supplementary material a detailed overview with all 
reported symptoms is in Section (F) Table 1. All asymp-
tomatic participants were recent high-risk contacts. From 
a total of 472 symptomatic patients, 423 (89.6%) reported 
onset of symptoms within the prior 7 days. A total of 146 
(19.2%) participants had a positive SARS-CoV-2 RT-PCR 
result, leading to a positivity rate of 29.7% (81 participants) 
in Berlin and 13.3% (65 participants) in Heidelberg. Of all 
symptomatic participants a total of 137 (28.2%) had a posi-
tive SARS-CoV-2 RT-PCR result whereas only 9 (3.3%) of 
the asymptomatic participants had a positive SARS-CoV-2 
RT-PCR result. The median viral load for all participants 
was 7.26  log10 SARS-CoV2 RNA copies/ml (IQR 3.7–9.4), 
with Berlin and Heidelberg differing only slightly (7.75 and 
6.97, respectively). Seven tests resulted in an error message 
by the LumiraDx™ device. Upon repeat from the same sam-
ple extraction buffer, all samples yielded valid results and 
were included in the analysis. Almost all participants were 
Table 1  Study population characteristics
Overall
Total N = 761
Heidelberg
Total N = 488
Berlin
Total N = 273
Age in years
Information available on N = 761
Median (IQR) 35.0 (27.0–42.0) 37.0 (28.0–53.0) 33.0 (27.0–42.0)
Gender
Information available on N = 759
Female N (%) 396 (52.2) 266 (54.7) 130 (47.6)
BMI > 25
Information available on N = 703
N (%) 327 (46.5) 243 (50.2) 84 (38.4)
Comorbidities
Information available on N = 760
N (%) 241 (31.7) 183 (37.6) 58 (21.2)
Symptoms on testing day
Information available on N = 758
N (%) 486 (64.1) 218 (44.8) 268 (98.2)
Duration of symptoms from day of testing in days
Information available on N = 472
Mean (SD) 3.9 (3.2) 3.7 (3.7) 4.1 (2.7)
Prior test performed and negative
Information available on N = 695
Yes N (%) 86 (12.4) 80 (16.6) 6 (2.8)
RT-PCR positives N (%) 146 (19.2) 65 (13.3) 81 (29.7)
Viral load  (log10 SARS-CoV2 RNA copies/ml)
Information available on N = 146
Median (IQR) 7.3 (3.7–9.4) 7.0 (3.4–8.5) 7.8 (3.8–9.4)
Fig. 2  Forest plot of sensitivity analysis overall and by subgroup for LumiraDx™. n number, TP true positives, FN false negatives, FP false 
positives, TN true negatives
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able to perform the self-sampling without issues, with only 
8 participants (1.1%) minorly deviating from the sample col-
lection protocol.
LumiraDx™ had an overall sensitivity of 82.2% (120 of 
146 RT-PCR positives detected; 95% CI 75.2–87.5%) and 
a specificity of 99.3% (95% CI 98.3–99.7%) (Fig. 2). The 
performance varied only slightly by site, with sensitivity of 
84.6% (95% CI 7.9–91.4%) and 80.2% (95% CI 70.3–87.5%) 
and specificity of 99.3% (95% CI 97.9–99.7%) and 99.5% 
(95% CI 97.1–100%) in Heidelberg and Berlin, respectively. 
The sensitivity was 89.6% (95% CI 83.0–93.8%) for sam-
ples with a viral load ≥ 5 log10 SARS-CoV2 RNA copies/
ml and 93.8% (95% CI 86.2–97.3%) for samples with a 
viral load ≥ 7 log10 SARS-CoV2 RNA copies/ml (Fig. 2). 
Sensitivity in different categories of viral load compared 
to the RT-PCR results is shown in Fig. 3. Similar, for sam-
ples with cycle threshold (CT) values < 25, the sensitivity 
was 92.6% (95% CI 85.6–96.4%) and for those with a CT-
value < 30, the sensitivity was 90.2% (95% CI 83.6–94.3%) 
(Fig. 2). Correspondingly, the sensitivity was 62.7% (95% CI 
49.0–74.7%) and 41.7% (95% CI 24.5–61.2%) for samples 
with a CT-value ≥ 25 and CT-value ≥ 30 (Fig. 2). Supple-
mentary Table 3 (Section (G)) shows a detailed listing of 
the viral load, CT-value and Ag-RDT result for each partici-
pant. Overall a moderate correlation was observed between 
the signal intensity (measured by the COI values) of the 
LumiraDx™ device and viral load, except for a few high 
viral load samples (5 with viral load > 7 log10 SARS-CoV2 
RNA copies/ml) that scored a low COI and were consid-
ered false-negative (supplement Section (H) Fig. 2). Spear-
man rank correlation coefficient was calculated to be 0.57 
between COI and viral load.
Out of 758 participants, 272 (35.9%) were asympto-
matic, high-risk contacts with nine RT-PCR confirmed 
positive cases, and eight Ag-RDT positive cases, resulting 
in a sensitivity of 77.8% with a wide confidence interval 
(95% CI 45.3–93.7%). The sensitivity among symptomatic 
participants was 82.5% (95% CI 75.3–87.9%) in comparison 
(Fig. 2). The median viral load values of the asymptomatic 
cohort and the symptomatic participants were 6.3 (IQR 
3.2–7.5) and 7.4 (IQR 3.7–9.4)  log10 SARS-CoV2 RNA 
Fig. 3  Sensitivity of LumiraDx™ compared to viral load for all RT-PCR positive participants. Viral load unit:  log10 SARS-CoV2 RNA copies/
ml
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copies/ml, respectively. Figure 4 shows the sensitivity across 
asymptomatic and symptomatic participants by viral load.
With respect to a possible impact of duration of illness, 
the overall sensitivity of the Ag-RDT was found to increase 
slightly to 83.2% (95% CI 75.9–88.6%), when restricting 
the analysis to the manufacturer-recommended 12 days 
post symptom onset (N = 461). Sensitivity was 86.4% (95% 
CI 79.1–91.5%), with 102 of 118 RT-PCR positive cases 
detected, when symptom duration was 7 days or less, com-
pared to 53.8% (95% CI 29.1–76.8%) for participants with a 
symptom duration of 8–14 days.
Discrepant analysis
Sufficient sample volume was available to evaluate three 
out of three Ag-RDT positive but RT-PCR negative cases 
(i.e., false positive) and only nine of 26 Ag-RDT negative 
but RT-PCR positive cases (i.e., false negative) with an RT-
PCR from the antigen buffer (thus 17 false-negative samples 
could not be retested). All but two out of nine false negatives 
tested negative. The two-testing positive on RT-PCR from 
the buffer showed a viral load likely below the analytical 
sensitivity of LumiraDx™ (4.5 and 2.6 log10 SARS-CoV2 
RNA copies/ml; supplement Section (I) Table 4).
Analytical sensitivity
To test the analytical sensitivity of LumiraDx™, a head-
to-head comparison with Abbott PanBio and SD Biosen-
sor Standard Q, using in vitro-propagated, live virus was 
employed. For this analysis, we tested the BavPat1 isolate 
produced in two different cell lines (VeroE6 and Calu-3) 
as well as an additional patient isolate (HD isolate). This 
analysis showed LumiraDx™ to have superior sensitivity 
to the two lateral flow assays (Fig. 5) across the three tested 
viruses. The analytical limit of detection was estimated in 
the range of 2.1–55.6 PFU for LumiraDx™ which compared 
to 52.9–1,428.6 PFU and 8.8–238.1 PFU for the Abbott Pan-
Bio and SD Biosensor Standard Q, respectively. The dif-
ference in sensitivity observed for the Calu3 stock is likely 
due to a lower number of virus particles in the input after 
correction for infectious titers (supplement Section J, Fig. 3).
Exclusivity testing
No cross-reactivity was detected among a wide array of 
respiratory pathogens and commensals tested, including 
the endemically circulating human coronaviruses. Detailed 
Fig. 4  LumiraDx™ results according to viral load by presence of symptoms and days since symptom onset for all RT-PCR positive participants. 
Viral load unit:  log10 SARS-CoV2 RNA copies/ml
 L. J. Krüger et al.
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results of the exclusivity testing are reported in Table 5 in 
Section (K) in the supplementary material.
System usability scale (SUS) and ease‑of‑use 
assessment (EoU)
In the SUS, the LumiraDx™ scored 65 out of 100 points. 
The system was considered easy to use without much train-
ing required. However, the test device is not suitable for 
batch testing. The throughput within 8 h working shifts is a 
maximum of 24 tests per device, as only one sample can be 
processed at a time and the device requires 12-min analysis 
time, in addition to a 5-min disinfection and drying pro-
cedure. A total storage time of 5 h after sample extraction 
from patients allows for testing to be organized sequentially 
and most likely capture the maximal throughput in a day 
(supplement Section (J) Fig. 3 System Usability Score and 
EoU results).
Discussion
This multi-centre clinical diagnostic accuracy study demon-
strates a high sensitivity of 82.2%, meeting the WHO recom-
mended cut-off of 80% [4] and an excellent specificity of 
99.3% for the evaluated LumiraDx™ microfluidic immu-
nofluorescence test in a clinical setting. For participants 
with high viral load (≥ 7  log10 SARS-CoV2 RNA copies/
ml) who are presumably responsible for most secondary 
transmissions, the test showed an even higher sensitivity 
(93.8%) [23]. The assay detected most positive cases within 
the first week of symptoms, with a sensitivity of 86.4% (95% 
CI 79.1–91.5%). In addition, the analytical sensitivity evalu-
ated in a laboratory setting was excellent and surpassed that 
of other Ag-RDTs.
The sensitivity observed in a clinical setting of the 
LumiraDx™ in this study was not better than well perform-
ing lateral flow assays that can be read with the naked eye 
in other studies [8, 9]. The two WHO-recommended Ag-
RDTs, the SD Biosensor Standard Q and Abbott PanBio 
demonstrated sensitivities ranging from 76.6 to 85.0% in our 
studies preceding this study [8, 24]. However, as we were 
not able to perform the tests head-to-head to allow a direct 
comparison, the differences may be attributable to different 
phases of the pandemic with different test-positive ratios. 
Although the test-positive ratio during the LumiraDx™ 
study was higher, absolute viral load and viral load distri-
bution were similar in our PanBio study that immediately 
preceded this study [8].
Another explanation for the lack of superior clinical sen-
sitivity for LumiraDx™ could be the use of NMT sampling 
in contrast to NP sampling for the aforementioned lateral 
flow assays as NP sampling remains the gold standard [25]. 
To what extent, however, the NMT sampling (the manu-
facturer recommended sample type) reduces sensitivity is 
unclear. A recent Swedish study suggested a reduction of 3% 
with NMT sampling for LumiraDx™, while a head-to head 
study in our hands with another Ag-RDT showed largely 
Fig. 5  Analytical sensitivity of 
LumiraDx™ in comparison to 
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equivalent performance [25–27]. Also, important to note is 
that the manufacturer recommended professional-collected 
NMT sampling while we asked our study participants to 
self-collect their sample under professional supervision. 
However, none of the false-negative samples in our study 
had observed deviations from the optimal sampling proce-
dure, therefore, though self-collection is not recommended 
by the supplier and could have introduced variability, this 
is unlikely to have been the case. Also, recent data from 
other studies comparing observed self- and professional-
swab sampling shows this to be unlikely as a source of large 
variability [26].
Nevertheless, inter-sample variability or differing distri-
bution of virus in the nasal area during the illness course 
could account for some false negative results, as supported 
by the two samples in which virus was identified in very low 
amounts when antigen buffer was retested by RT-PCR, while 
the viral load was high in the NP sample used for RT-PCR 
routine testing.
Our study shows a substantially lower clinically sensitiv-
ity than the study by Drain et al. [15]. While detailed com-
parisons are limited without access to the data of the Drain 
study, we would consider the participant populations to be 
similar, apart from the fact that we had double the percent-
age of asymptomatic participants. Another important differ-
ence of note is in the swabs used. While the study by Drain 
et al. utilized a flocked swab, we utilized a standard rayon 
swab, supplied by the manufacturer, which might contribute 
to less virus being captured in our study [28].
The analytical results of the study confirm the claim of 
the manufacturer to have superior sensitivity over the two 
other Ag-RDTs studied. Importantly, values obtained for 
the PanBio and Standard Q in our study were similar to 
previous studies [29]. Reasons for the high analytical sen-
sitivity not translating into high clinical sensitivity could 
relate to problems in the extraction of the virus. However, 
the samples with high viral load that went undetected did 
not have any particular characteristics (consistency, blood 
contamination), leaving the reasons for the possible extrac-
tion problems unexplained. Another consideration could 
be immune escape due to viral variants not recognized 
by the antibodies included in the test. This could explain 
variable performance between two geographically distinct 
sites (in the Pacific North West of the USA in the study by 
Drain et al. [15] and Germany). However, this appears very 
unlikely given the multiple antibodies used in the test that 
target the nucleocapsid, which is a rather conserved target 
even in recent strain variants [30]. While a hook or prozone 
effect could be considered, it appears unlikely in light of the 
sample type and has not been shown in prior experiments 
by the manufacturer [12]. Thus, further studies are needed 
to explain the lower clinical sensitivity of LumiraDx™ for 
some high viral load samples and the differences observed 
in clinical and analytical sensitivity.
Nevertheless, it is to note, that the RT-PCR reference 
standard also has its limitations, as it is not always a 
meaningful test when considering viable virus and risk of 
transmission [31]. This is also demonstrated by a recent 
study of an Ag-RDT in the USA, where the sensitivity 
was 92.6% in symptomatic individuals when compared 
to viral culture versus 64.2% when compared to RT-PCR 
[32]. Thus, using the RT-PCR reference standard, we 
might have underestimated the performance of the Ag-
RDT when it comes to detection of viable virus.
We also acknowledge that the Lumira assay is only 
recommended for symptomatic patients. Sensitivity was 
slightly higher among symptomatic patients (82.5%, 95% 
CI 75.3–87.9%) as compared to asymptomatic individuals 
(77.8%, 45.3–93.7%), with overlapping confidence inter-
vals. This was to be expected from the lower viral load 
observed in the limited number of asymptomatic positive 
cases. As cohort studies have shown the viral load kinetics 
between asymptomatic and symptomatic infections to be 
similar, the findings of the lower viral load and thus lower 
sensitivity observed in our study is most likely attributable 
to chance or to capturing asymptomatic patients too early 
(maybe also prior to symptom development) or too late. 
Further need for studies remain to better understand the 
performance in asymptomatic patients [33].
The excellent clinical specificity of the LumiraDx™ 
was confirmed by the analytical exclusivity testing. Our 
findings indicate no cross-reactivity with the eleven tested 
pathogens or commensals that would lead to false-positive 
Ag-RDT results. Assuming a SARS-CoV-2 prevalence of 
1%, a test with the performance of the LumiraDx™ would 
result in a positive predictive value (PPV) of 45.8% and a 
negative predictive value (NPV) of 99.8%. At a prevalence 
of 3%, PPV would be 78.7% and NPV 99.5%.
The NMT sampling was considered highly favourable 
based on participants feedback in comparison to the NP 
sampling. In addition, NMT self-sampling under pro-
fessional supervision would enable a higher sampling 
throughput, requiring fewer medical personnel and less 
protective equipment used (e.g., the sampling could be 
observed through a window). Another very favourable 
aspect of the test is the possibility for results to be reported 
automatically and recorded digitally to be uploaded in 
information systems, which is an important characteristic 
when it comes to surveillance and supply chain manage-
ment. On the other hand, the device-based assay does not 
allow for batch testing and has a limited throughput. In 
addition, a testing approach using an automated immuno-
assay platform solution could introduce additional chal-
lenges, for example in regard to regular maintenance or 
infrastructure requirements (such as stable electricity), 
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which might only be possible in a well-resourced setting. 
Thus, our observations show the LumiraDx™ to likely be 
most useful in an environment where persons to be tested 
arrive over time, such as a medical office or emergency 
room with all the required resources available. The device-
based LumiraDx™ system may also lend itself to simul-
taneous testing for several respiratory pathogens from the 
same patient sample, which could facilitate the workup of 
individuals presenting with non-specific respiratory symp-
toms, e.g., during the influenza season.
Overall, our study has several strengths. The study sites 
in Heidelberg and Berlin enrolled participants representa-
tive of the current pandemic observed in Germany. The 
study participants represented the age groups above 18 most 
commonly presenting for testing in an ambulatory setting 
and including asymptomatic and symptomatic participants 
across the two study sites, making the findings generalizable 
to ambulatory test settings across Germany. The accuracy of 
the Ag-RDT was evaluated using several measures, includ-
ing clinical accuracy, analytical sensitivity, and exclusivity. 
In addition, the ease-of-use assessment especially designed 
for this study, in combination with the standardized SUS, 
emphasized important points regarding the operationaliza-
tion of the test. Finally, this study was conducted in point-of-
care settings, representing the general diagnostic challenges 
of near patient testing.
However, our study also has limitations. The population 
was preselected by the local health department’s testing cri-
teria based on national guidelines. As pandemic dynamics 
change, these criteria are regularly updated, yet no signifi-
cant differences were observed in enrolled study population 
groups over the study time in terms of comparability. The 
sub-analyses by Ct-value have limited comparability as three 
different RT-PCR standards were used for this study, using 
different assay targets, reagents, and technical equipment. 
To account for possible variability across tests in Ct-values, 
viral load was calculated using a standardized calibrated 
method and used for the comparisons.
In conclusion, we demonstrate that the LumiraDx™ assay 
has comparable clinical sensitivity and higher analytical sen-
sitivity than WHO-approved lateral-flow Ag-RDTs, paired 
with excellent specificity and operational characteristics 
suitable for low-throughput settings.
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